Sequential EPA and GLA Administration for 8-HOA Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers and inflammatory diseases are in need of enhancement in effectiveness, particularly in targeting Cox-2 over-expressing diseases and diseases responsive to histone deacetylase inhibitors.
Innovation Solution
Administering eicosapentaenoic acid (EPA) for a first period to accumulate a baseline level, followed by gamma-linolenic acid (GLA) to promote the production of 8-hydroxyoctanoic acid (8-HOA) in vivo, thereby inhibiting the conversion to arachidonic acid and enhancing the effectiveness of primary treatments such as COX-2 inhibitors and histone deacetylase inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for cancers and inflammatory diseases are used, then basic treatment efficacy is achieved, but treatment effectiveness is insufficient and needs enhancement
Solution Approach 1:
The patent combines EPA and GLA fatty acids with conventional treatments (COX-2 inhibitors and HDAC inhibitors) to create a synergistic therapeutic approach. The fatty acid combination enhances the efficacy of these conventional treatments by modulating inflammatory pathways and gene expression, thereby improving overall treatment effectiveness and disease resolution rates.
Solution Approach 2:
The patent utilizes changes in fatty acid metabolism parameters by administering EPA followed by GLA to alter the biochemical environment. This parameter change promotes the production of anti-inflammatory mediators and inhibits pro-inflammatory pathways, thereby enhancing the effectiveness of conventional treatments without increasing their toxicity.
2Object-affected harmful factors
If COX-2 inhibitors and HDAC inhibitors are administered, then disease symptoms are suppressed, but treatment resistance and harmful side effects increase
Solution Approach 1:
The patent introduces EPA and GLA as intermediary substances that modulate the interaction between conventional treatments and disease pathways. These fatty acids act as mediators that enhance the anti-tumor and anti-inflammatory effects of COX-2 inhibitors and HDAC inhibitors while reducing their harmful side effects and treatment resistance through modulation of inflammatory signaling pathways.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Increased production of 8-HOA aids in improving the efficacy of treatments for Cox-2 over-expressing diseases and diseases responsive to HDAC inhibitors, offering a complementary therapeutic approach.
Implementation Method 1
Accumulating a baseline level of EPA in the cells of the patient, prior to administering GLA, promotes production of 8-HOA instead of arachidonic acid (AA) and its downstream products
Implementation Method 2
Gamma linoleic acid (GLA, 18:3n-6) is an omega-6 fatty acid that is found in some plant oils, primarily evening primrose and borage oils. It is also formed via metabolism of linoleic acid (LA, 18:2n-6) by Δ6-desaturase
Implementation Method 3
COX-2 catalyzed peroxidation of DGLA also leads to the formation of 8-HOA
Data Source
AI summary
The present disclosure relates to methods of treating diseases. More particularly, the disclosure relates to methods of adjuvant therapy. Disclosed herein are methods of promoting 8-hydroxyoctanoic acid (8-HOA) production and thereby treating diseases. The method includes administering for a first period of time a first dosage form including eicosapentaenoic acid (EPA) to a patient. After expiration of the first period of time, the patient is then administered for a second period of time a second dosage form including gamma-linolenic acid (GLA).